Almitrine

Summary

Almitrine (CHEMBL1183717) is an approved small-molecule central nervous system stimulant (ATC R07AB07); indicated across 3 conditions including respiratory system disorder and respiratory failure.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R07AB07
• Indications: 3 conditions
• Clinical trials: 2
• Chemistry: 477.6 Da · C26H29F2N7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1183717
Name	Almitrine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	33887
ChEBI	CHEBI:53778
ATC	R07AB07
Molecular formula	C26H29F2N7
Molecular weight	477.6
InChIKey	OBDOVFRMEYHSQB-UHFFFAOYSA-N

SMILES: C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C

IUPAC name: 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine

ChEBI definition: A triamino-1,3,5-triazine compound having allylamino substituents at the 2- and 4-positions and a 4-(bis(p-fluorophenyl)methyl)-1-piperazinyl group at the 6-position.

Pharmacological roles (ChEBI): central nervous system stimulant.

Also known as: Almitrina, Almitrine, ALMITRINE, almitrine, Almitrine dimesilate

Parent form; salt/anhydrous children: CHEMBL314610, CHEMBL3181957

Patent coverage: 285 distinct patent families (838 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Kappa-type opioid receptor.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
respiratory system disorder	4	MONDO:0005087	EFO:0000684
respiratory failure	3	MONDO:0021113	EFO:0009686
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04357457	PHASE3	COMPLETED	Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia
NCT05216575	Not specified	COMPLETED	Almitrine in COVID-19 Patients With ARDS Treated by HFNO

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).